Association study of HLA with the kinetics of SARS-CoV-2 spike specific IgG antibody responses to BNT162b2 mRNA vaccine
Association study of HLA with the kinetics of SARS-CoV-2 spike specific IgG antibody responses to BNT162b2 mRNA vaccine
复制标题
HLA 与 SARS-CoV-2 刺突特异性 IgG 抗体对 BNT162b2 mRNA 疫苗反应动力学的关联研究
DOI：
10.1101/2022.02.01.22270285
复制
发表时间：
2022
影响因子：
1.6
通讯作者：
K. Tokunaga
中科院分区：
文献类型：
--
作者：
Seik;Y. Omae;J. Takeuchi;A. Fukunaga;S. Yamamoto;A. Tanaka;K. Matsuda;M. Kimura;K. Maeda;G. Ueda;T. Mizoue;M. Ujiie;H. Mitsuya;N. Ohmagari;W. Sugiura;K. Tokunaga
BNT 162 b2是一种基于mRNA的SARS-CoV-2疫苗（辉瑞-BioNTech），是最有效的COVID-19疫苗之一，已获得全球130多个国家的批准。然而，几项研究报告称，COVID-19疫苗在体液和细胞应答方面显示出高度的人际变异性，例如SARS-CoV-2刺突蛋白免疫球蛋白（IG）G、伊加、IgM、中和抗体以及CD 4+和CD 8 + T细胞。本研究的目的是调查来自日本东京国立全球健康和医学中心（NCGM）中心医院的100名医院工作人员中抗SARS-CoV-2刺突IgG（IgG-S）谱和不良反应的动态变化及其与HLA谱的相关性。DQA 1 *03：03：01（P = 0.017;比值比（OR）2.80，95%置信区间（CI）1.05-7.25）与两剂BNT 162 b2后较高的IgG-S产量显著相关，而DQB 1 *06：01：01：01（P = 0.028，OR 0.27，95%CI 0.05-0.94）与两剂BNT 162 b2后IgG-S下降显著相关。没有HLA等位基因与局部症状或发热显著相关。然而，C*12：02：02（P = 0.058; OR 0.42，95%CI 0.15-1.16），B*52：01：01（P = 0.031; OR 0.38，95%CI 0.14-1.03），DQA 1 *03：02：01（P = 0.028; OR 0.39，95%CI 0.15-1.00）和DPB 1 *02：01：02（P = 0.024; OR 0.45，95%CI 0.21-0.97）似乎与两剂BNT 162 b2疫苗接种后针对全身症状的保护显著相关。显然有必要进行更大样本量的进一步研究，以确定HLA等位基因与COVID-19疫苗接种后IgG-S产生和长期可持续性的相关性。
BNT162b2, an mRNA-based SARS-CoV-2 vaccine (Pfizer-BioNTech), is one of the most effective COVID-19 vaccines and has been approved by more than 130 countries worldwide. However, several studies have reported that the COVID-19 vaccine shows high interpersonal variability in terms of humoral and cellular responses, such as those with respect to SARS-CoV-2 spike protein immunoglobulin (Ig)G, IgA, IgM, neutralizing antibodies, and CD4+ & CD8+ T cells. The objective of this study is to investigate the kinetic changes in anti-SARS-CoV-2 spike IgG (IgG-S) profiles and adverse reactions and their associations with HLA profiles among 100 hospital workers from the Center Hospital of the National Center for Global Health and Medicine (NCGM), Tokyo, Japan. DQA1*03:03:01 (P = 0.017; Odd ratio (OR) 2.80, 95%Confidence interval (CI) 1.05-7.25) was significantly associated with higher IgG-S production after two doses of BNT162b2 while DQB1*06:01:01:01 (P = 0.028, OR 0.27, 95%CI 0.05-0.94) was significantly associated with IgG-S declines after two doses of BNT162b2. No HLA alleles were significantly associated with either local symptoms or fever. However, C*12:02:02 (P = 0.058; OR 0.42, 95%CI 0.15-1.16), B*52:01:01 (P = 0.031; OR 0.38, 95%CI 0.14-1.03), DQA1*03:02:01 (P = 0.028; OR 0.39, 95%CI 0.15-1.00) and DPB1*02:01:02 (P = 0.024; OR 0.45, 95%CI 0.21-0.97) appeared significantly associated with protection against systemic symptoms after two doses of BNT162b2 vaccination. Further studies with larger sample sizes are clearly warranted to determine HLA allele associations with the production and long-term sustainability of IgG-S after COVID-19 vaccination.
影响因子：
3.4
作者：
Karikó, K;Kuo, A;Langer, DJ
通讯作者：
Langer, DJ
DOI：
10.1073/pnas.0403492101
发表时间：
2004-06-29
影响因子：
11.1
作者：
Buchholz, UJ;Bukreyev, A;Collins, PL
通讯作者：
Collins, PL
影响因子：
2.7
作者：
Pappas DJ;Marin W;Hollenbach JA;Mack SJ
通讯作者：
Mack SJ